Table 5. Joint effects between RASA2, CADM1 and HIF1AN polymorphisms and WC on breast cancera.
| Genotype | WC < 80 cm | WC ≥ 80 cm | ||
|---|---|---|---|---|
| Case/Ctrl | OR (95% CI)b | Case/Ctrl | OR (95% CI)b | |
| RASA2 (rs16851483) | ||||
| G/G | 102/190 | 1.00 (referent) | 302/312 | 1.91 (1.38–2.65) |
| G/T | 76/138 | 1.18 (0.79–1.75) | 259/227 | 2.35 (1.68–3.29) |
| T/T | 11/20 | 1.41 (0.63–3.16) | 47/31 | 3.36 (1.94–5.83) |
| G/T+T/T | 87/158 | 1.21 (0.82–1.77) | 306/258 | 2.47 (1.78–3.44) |
| Interaction | Additive: | RERI = 3.48 (−0.61 to7.56) | ||
| AP = 0.62 (0.44–0.80) | ||||
| S = 4.12 (2.95–5.75) | ||||
| Multiplicative: | ROR = 2.42 (1.74–3.37) | |||
| CADM1 (rs12286929) | ||||
| G/A | 58/149 | 1.00 (referent) | 227/232 | 2.68 (1.81–3.97) |
| A/A | 117/175 | 1.81 (1.20–2.73) | 325/295 | 2.94 (2.01–4.29) |
| G/G | 13/27 | 1.40 (0.66–3.00) | 56/47 | 3.22 (1.86–5.56) |
| A/A+G/G | 130/202 | 1.75 (1.17–2.62) | 381/342 | 2.97 (2.05–4.32) |
| Interaction | Additive: | RERI = 9.84 (−2.57 to 22.26) | ||
| AP = 0.75 (0.59–0.90) | ||||
| S = 5.18 (3.13–8.58) | ||||
| Multiplicative: | ROR = 2.90 (2.00–4.22) | |||
| HIF1AN (rs17094222) | ||||
| T/T | 79/163 | 1.00 (referent) | 266/265 | 1.95 (1.37–2.76) |
| T/C | 92/143 | 1.17 (0.78–1.75) | 275/238 | 2.30 (1.62–3.26) |
| C/C | 17/43 | 0.85 (0.44–1.62) | 68/71 | 1.83 (1.14–2.92) |
| T/C+C/C | 109/186 | 1.09 (0.74–1.61) | 343/309 | 2.19 (1.56–3.08) |
| Interaction | Additive: | RERI = 2.43 (−0.81 to5.67) | ||
| AP = 0.55 (0.33–0.77) | ||||
| S = 3.47 (2.44–4.94) | ||||
| Multiplicative: | ROR=2.14 (1.52–3.01) | |||
a Missing data were excluded from analysis.bAdjusted for age (continuous), education level, marital status, residence area, previous income (continuous), using of hormone drugs, moderate exercise (continuous), first-degree family history of breast cancer and menopausal status.